These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

2229 related articles for article (PubMed ID: 25923549)

  • 1. AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer.
    Jänne PA; Yang JC; Kim DW; Planchard D; Ohe Y; Ramalingam SS; Ahn MJ; Kim SW; Su WC; Horn L; Haggstrom D; Felip E; Kim JH; Frewer P; Cantarini M; Brown KH; Dickinson PA; Ghiorghiu S; Ranson M
    N Engl J Med; 2015 Apr; 372(18):1689-99. PubMed ID: 25923549
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FDA Benefit-Risk Assessment of Osimertinib for the Treatment of Metastatic Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor T790M Mutation.
    Odogwu L; Mathieu L; Goldberg KB; Blumenthal GM; Larkins E; Fiero MH; Rodriguez L; Bijwaard K; Lee EY; Philip R; Fan I; Donoghue M; Keegan P; McKee A; Pazdur R
    Oncologist; 2018 Mar; 23(3):353-359. PubMed ID: 29242281
    [TBL] [Abstract][Full Text] [Related]  

  • 3. First-in-human phase I study of BEBT-109 in previously treated EGFR exon 20 insertion-mutated advanced non-small cell lung cancer.
    Zeng L; Song L; Liu L; Wu F; Xu Q; Yan H; Lin S; Jiang W; Wang Z; Deng L; Qin H; Zhang X; Xiao J; Liu M; Liu Z; Zhang L; Zhou C; Xiong Y; Wang Y; Zhang Y; Yang N
    Med; 2024 May; 5(5):445-458.e3. PubMed ID: 38521070
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of a mutant-selective covalent inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLC.
    Walter AO; Sjin RT; Haringsma HJ; Ohashi K; Sun J; Lee K; Dubrovskiy A; Labenski M; Zhu Z; Wang Z; Sheets M; St Martin T; Karp R; van Kalken D; Chaturvedi P; Niu D; Nacht M; Petter RC; Westlin W; Lin K; Jaw-Tsai S; Raponi M; Van Dyke T; Etter J; Weaver Z; Pao W; Singh J; Simmons AD; Harding TC; Allen A
    Cancer Discov; 2013 Dec; 3(12):1404-15. PubMed ID: 24065731
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact on prognosis of rebiopsy in advanced non-small cell lung cancer patients after epidermal growth factor receptor-tyrosine kinase inhibitor treatment: a systematic review.
    Imakita T; Matsumoto H; Hirano K; Morisawa T; Sakurai A; Kataoka Y
    BMC Cancer; 2019 Jan; 19(1):105. PubMed ID: 30683066
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II Study of Osimertinib in Patients With Epidermal Growth Factor Receptor Mutations: Results From the NCI-MATCH ECOG-ACRIN (EAY131) Trial Subprotocol E.
    Chen MF; Song Z; Yu HA; Sequist LV; Lovly CM; Mitchell EP; Moscow JA; Gray RJ; Wang V; McShane LM; Rubinstein LV; Patton DR; Williams PM; Hamilton SR; Umemura Y; Tricoli JV; Conley BA; Arteaga CL; Harris LN; O'Dwyer PJ; Chen AP; Flaherty KT
    JCO Precis Oncol; 2024 Apr; 8():e2300454. PubMed ID: 38591867
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Early dose reduction of osimertinib in advanced EGFR -mutated non-small cell lung cancer.
    Ferreira M; Ebia MI; Reckamp KL
    Anticancer Drugs; 2024 Aug; 35(7):672-679. PubMed ID: 38527329
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acquired resistance to AZD9291 as an upfront treatment is dependent on ERK signaling in a preclinical model.
    Ku BM; Choi MK; Sun JM; Lee SH; Ahn JS; Park K; Ahn MJ
    PLoS One; 2018; 13(4):e0194730. PubMed ID: 29641535
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase 1 study of twice weekly pulse dose and daily low-dose erlotinib as initial treatment for patients with EGFR-mutant lung cancers.
    Yu HA; Sima C; Feldman D; Liu LL; Vaitheesvaran B; Cross J; Rudin CM; Kris MG; Pao W; Michor F; Riely GJ
    Ann Oncol; 2017 Feb; 28(2):278-284. PubMed ID: 28073786
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multi-institutional study of osimertinib dose-optimization in non-small cell lung cancer patients with EGFR activating mutation aged 70 years or older ('MONEY' trial).
    Tsukita Y; Taguri M; Goto Y; Hosomi Y; Mizutani T; Watanabe K; Yoh K; Takahashi S; Kubota K; Kunitoh H
    Jpn J Clin Oncol; 2024 Jun; 54(6):730-734. PubMed ID: 38520037
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment Outcomes and Safety of Mobocertinib in Platinum-Pretreated Patients With EGFR Exon 20 Insertion-Positive Metastatic Non-Small Cell Lung Cancer: A Phase 1/2 Open-label Nonrandomized Clinical Trial.
    Zhou C; Ramalingam SS; Kim TM; Kim SW; Yang JC; Riely GJ; Mekhail T; Nguyen D; Garcia Campelo MR; Felip E; Vincent S; Jin S; Griffin C; Bunn V; Lin J; Lin HM; Mehta M; Jänne PA
    JAMA Oncol; 2021 Dec; 7(12):e214761. PubMed ID: 34647988
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An oligoclonal antibody durably overcomes resistance of lung cancer to third-generation EGFR inhibitors.
    Mancini M; Gal H; Gaborit N; Mazzeo L; Romaniello D; Salame TM; Lindzen M; Mahlknecht G; Enuka Y; Burton DG; Roth L; Noronha A; Marrocco I; Adreka D; Altstadter RE; Bousquet E; Downward J; Maraver A; Krizhanovsky V; Yarden Y
    EMBO Mol Med; 2018 Feb; 10(2):294-308. PubMed ID: 29212784
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer: distinct natural history of patients with tumors harboring the T790M mutation.
    Oxnard GR; Arcila ME; Sima CS; Riely GJ; Chmielecki J; Kris MG; Pao W; Ladanyi M; Miller VA
    Clin Cancer Res; 2011 Mar; 17(6):1616-22. PubMed ID: 21135146
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A multicenter, phase I, pharmacokinetic study of osimertinib in cancer patients with normal renal function or severe renal impairment.
    Vishwanathan K; Sanchez-Simon I; Keam B; Penel N; de Miguel-Luken M; Weilert D; Mills A; Marotti M; Johnson M; Ravaud A
    Pharmacol Res Perspect; 2020 Aug; 8(4):e00613. PubMed ID: 32567817
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Integrated PBPK-EO modeling of osimertinib to predict plasma concentrations and intracranial EGFR engagement in patients with brain metastases.
    Liang F; Zhang Y; Xue Q; Zhang X
    Sci Rep; 2024 Jun; 14(1):12736. PubMed ID: 38830973
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of selective irreversible inhibitors for EGFR-T790M.
    Zhou W; Ercan D; Jänne PA; Gray NS
    Bioorg Med Chem Lett; 2011 Jan; 21(2):638-43. PubMed ID: 21208802
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of epidermal growth factor receptor tyrosine kinase inhibitors against EGFR T790M. Mutation in non small-cell lung carcinoma.
    Wang Y; Guo Z; Li Y; Zhou Q
    Open Med (Wars); 2016; 11(1):68-77. PubMed ID: 28352770
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Heterogeneous Mechanisms of Primary and Acquired Resistance to Third-Generation EGFR Inhibitors.
    Ortiz-Cuaran S; Scheffler M; Plenker D; Dahmen L; Scheel AH; Fernandez-Cuesta L; Meder L; Lovly CM; Persigehl T; Merkelbach-Bruse S; Bos M; Michels S; Fischer R; Albus K; König K; Schildhaus HU; Fassunke J; Ihle MA; Pasternack H; Heydt C; Becker C; Altmüller J; Ji H; Müller C; Florin A; Heuckmann JM; Nuernberg P; Ansén S; Heukamp LC; Berg J; Pao W; Peifer M; Buettner R; Wolf J; Thomas RK; Sos ML
    Clin Cancer Res; 2016 Oct; 22(19):4837-4847. PubMed ID: 27252416
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drug-resistant EGFR mutations promote lung cancer by stabilizing interfaces in ligand-free kinase-active EGFR oligomers.
    Iyer RS; Needham SR; Galdadas I; Davis BM; Roberts SK; Man RCH; Zanetti-Domingues LC; Clarke DT; Fruhwirth GO; Parker PJ; Rolfe DJ; Gervasio FL; Martin-Fernandez ML
    Nat Commun; 2024 Mar; 15(1):2130. PubMed ID: 38503739
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cutaneous adverse events following treatment with third-generation EGFR tyrosine kinase inhibitors.
    Li Pomi F; Vaccaro F; Borgia F; Irrera N; Vaccaro M
    Ital J Dermatol Venerol; 2024 Apr; 159(2):212-214. PubMed ID: 38261309
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 112.